Replies to post #405 on Merck and Co Inc (MRK)

[DewDiligence]

Keytruda monotherapy in 2L-HCC misses primary endpoints in KEYNOTE-240 study with HR-0.78 for both PFS and OS:

https://www.businesswire.com/news/home/20190219005993/en/Merck-Update-KEYNOTE-240-Phase-3-Study-KEYTRUDA